Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

Published:2020-08-12 Issue:17 Volume:21 Page:2091-2099
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Altavilla Amelia¹,Casadei Chiara¹,Lolli Cristian¹,Menna Cecilia¹,Ravaglia Giorgia²,Gurioli Giorgia³,Farolfi Alberto¹,Brighi Nicole¹,Conteduca Vincenza¹,Burgio Salvatore Luca¹,Schepisi Giuseppe¹,Rossi Lorena¹,Gargiulo Stefania³,Lisotti Ivana⁴,De Giorgi Ugo¹

Affiliation:

1. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

2. Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

3. Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

4. Pharmacy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1803281

Reference57 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTS

3. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

4. Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMAx-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer;2024-04-26

2. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer;European Journal of Medicinal Chemistry;2024-03

3. Deregulated transcription factors in the emerging cancer hallmarks;Seminars in Cancer Biology;2024-01

4. Novel treatment strategies to overcome resistance in prostate cancer;Therapy Resistance in Prostate Cancer;2024

5. Challenges in therapeutic drug monitoring of digoxin and other antiarrhythmic drugs;Therapeutic Drug Monitoring;2024